Pharmaceutical testing relies heavily on animal models for regulatory approval. Understanding both the welfare costs and the scientific limitations of current animal testing frameworks advances both welfare and research quality.
Pharmaceutical animal testing welfare involves the convergence of welfare cost and scientific critique: many animal models predict human drug responses poorly, meaning the welfare cost of animal use is not offset by reliable scientific benefit. This dual critique — animals suffer, and the results often do not translate — is more powerful than welfare alone in changing regulatory frameworks. The FDA Modernization Act 2.0 reflects this converging argument. Alternative methods including organ-on-chip, organoids, advanced cell culture systems, and AI toxicology prediction are increasingly scientifically credible and welfare-superior. The transition is not instantaneous — regulatory validation of alternatives requires evidence accumulation — but the trajectory is clear. Welfare advocates who engage with the scientific quality arguments for alternative methods, not just the ethical arguments, are more persuasive to regulators and researchers.